

Board Changes and Executive Restructuring

Emyria Limited (ASX: EMD) ('Emyria', or the 'Company') an integrated clinical drug development and care delivery firm specialising in mental health, neuropsychiatry, and select neurological conditions, announces an update to its Board composition.

Dr. Alistair Vickery has retired from the Board and will shift his expertise from Board responsibilities to concentrate on clinical service expansion, particularly as Emyria advances its MDMA-assisted therapy programs.

Additional Board transitions include:

- Dr. Stewart Washer will move to Non-Executive Chairman from Executive Chairman and his salary will move from \$200k per annum to a total fee of \$80k per annum and;
- Dr. Karen Smith to Non-Executive Director with a salary in line with all current Non-Executive Directors.

With these changes, all Emyria Board Directors, with the exception of the Managing Director, have moved to Non-Executive roles. This streamlining is expected to halve annual Board costs, reflecting the Company's commitment to cost efficiency and a strategic focus on advancing the Company's active MDMA-assisted therapy programs and novel drug development initiatives.

All changes are effective immediately.

Emyria's Non-Executive Chair, Dr. Stewart Washer, commented: *"We thank Dr. Alistair Vickery for his invaluable contributions to the Board. His insight and dedication have been a driving force behind Emyria's growth. As Dr. Vickery transitions to focus on the clinical expansion of our MDMA-assisted therapy and mental health programs, we are confident his expertise will be instrumental in our pursuit to redefine mental health care."*

This release has been approved by the Board of Emyria.

FOR FURTHER INFORMATION

Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com

Sufian Ahmad
Corporate Advisor
+61 (0) 412 316 162
info@62capital.com.au

Emyria Limited is a clinical services and drug development company focused on revolutionising patient outcomes in neuroscience and mental health via a unique business model:

generates

Emyria Clinics: Deliver evidence-based and emerging therapies for mental health and other unmet needs across multiple sites (Emerald Clinics and The Pax Centre)

informs


Emyria Data: Robust and ethically-sourced Real-World Data gathered with patients and integrated into an advanced data platform powered by Palantir. Emyria data is used to improve Emyria's distinct therapy and drug development programs.

Emyria Drug Discovery: One of the world's largest libraries of unique MDMA-like compounds developed in partnership with the University of Western Australia seeking new psychedelic-assisted therapies and treatments for neurological diseases.

Emyria Drug Development: A suite of unique, highly potent dose forms of Ultra-Pure cannabinoids seeking registration for a range of mental health and neuroscience indications.

EMYRIA'S INTERACTIVE INVESTOR HUB

Investorhub.emyria.com Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



The Pax Centre specialises in treating individuals grappling with the psychological impacts of traumatic experiences. Our treatment approach is highly personalised, addressing a wide range of mental health issues, from PTSD and depression to anxiety disorders and substance abuse, often stemming from various life traumas.

Complex trauma, characterised by repeated, relational traumatic events often occurring during developmental stages, requires specialised attention due to its pervasive and lasting impact. In these cases, The Pax Centre prioritises early diagnosis and evidence-based treatments.

We also focus on proactive strategies for health expansion and personal growth, empowering our clients with skills and tools to improve wellbeing and performance. At the Pax Centre, we believe in transforming lives through focused, evidence-based mental health care.



Emerald Clinics is an Australian-based, patient-centric clinical service specialising in providing treatments for patients with complex and chronic conditions, where traditional therapies might not have yielded satisfactory results.

Leveraging our deep expertise with unregistered medicines, such as cannabinoids, we strive to pioneer and personalise care for our patients. Our robust, ethically-sourced data collection methods underpin our commitment to improving patient outcomes and advancing healthcare innovation.

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.